DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome. METHODS: This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used skewed logistic regression to describe the effect of antibiotic exposure on patient outcome. RESULTS: We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (interquartile range [IQR], 48-73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18 (IQR, 14-24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50% f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68; P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR, 1.02 and 1.56, respectively; P < .03), with significant interaction with sickness severity status. CONCLUSIONS: Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic exposure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these most seriously ill patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association (167,(171)(172)(173).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [171]
In the citing paper
“Antibiotics are subject to changes in PK/PD parameters in sepsis and septic shock where resultant concentrations may be too low risking clinical failure, or too high leading to toxicity (Table 3) [237–239].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [238]
Citations
Cites
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376 · cited 1×
“Various demographic and clinical data were collected including age, sex, height, weight, presence of renal replacement therapy, and measures of organ function and levels of patient sickness severity as described by the APACHE II (Acute Physiology and Chronic Health Evaluation II) score [15] on admission and SOFA (Sequ…”
MethodKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109
International Study of the Prevalence and Outcomes of Infection in Intensive Care Units
Vincent, J.-L. (2009) · JAMA · doi:10.1001/jama.2009.1754 · Cited by 3,618
Vincent, J.-L., de Mendonca, A., Cantraine, F., Moreno, R., Takala, J., Suter, P. M., Sprung, C. L., Colardyn, F., & Blecher, S. (1998) · Critical Care Medicine · doi:10.1097/00003246-199811000-00016 · Cited by 3,463
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908 · cited 1×
“From a pharmacokinetic/pharmacodynamic (PK/PD) perspective, preclinical studies have defined these antibiotics to be time dependent, that is, the time for which the free (unbound) antibiotic concentration is maintained above the minimum inhibitory concentration (MIC) is the determinate factor associated with bacterial…”
BackgroundAntimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930 · cited 1×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundHarbarth, S., Garbino, J., Pugin, J., Romand, J. A., Lew, D., & Pittet, D. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.005 · Cited by 637
McKinnon, P. S., Paladino, J. A., & Schentag, J. J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.12.009 · Cited by 464 · cited 2×
“Whereas animal in vivo studies have defined an f T>MIC between 40% and 70% of the dosing interval as being necessary [11], retrospective clinical evaluations have suggested that larger drug exposures are required, with β-lactam concentrations up to 4 times the MIC for the entire dosing interval being suggested [12, 13…”
BackgroundResultSubtherapeutic Initial β-Lactam Concentrations in Select Critically Ill Patients
Udy, A. A., Varghese, J. M., Altukroni, M., Briscoe, S., McWhinney, B. C., Ungerer, J. P., Lipman, J., & Roberts, J. A. (2012) · Chest · doi:10.1378/chest.11-1671 · Cited by 414 · cited 1×
“These patients may have augmented renal clearances needing either higher doses or more frequent dosing to overcome increased drug elimination [22, 23].”
BackgroundSelf-citationAntibiotics in critically ill patients: A systematic review of the pharmacokinetics of β-lactams.
Gonçalves-Pereira, J., & Póvoa, P. (2011) · Critical Care · doi:10.1186/cc10441 · Cited by 408 · cited 2×
“It has been suggested that superior infection outcomes could be achieved in critically ill patients by optimization of the pharmacokinetic exposure of antibiotics [5, 6].”
Background
Cited by
Items 401–500 of 1,000
Laporte-Amargós, J., Ulldemolins, M., Puig‐Asensio, M., Tebé, C., Castro, S., Carratalà, J., & Gudiol, C. (2023) · Journal of Infection · doi:10.1016/j.jinf.2023.06.023 · Cited by 18
Fridlund, J., Woksepp, H., & Schön, T. (2016) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2016.07.020 · Cited by 18
Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
Marsot, A., Hraiech, S., Cassir, N., Daviet, F., Parzy, G., Blin, O., Papazian, L., & Guilhaumou, R. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106124 · Cited by 18
A Review of Extended and Continuous Infusion Beta-Lactams in Pediatric Patients
Imburgia, T. A., & Kussin, M. L. (2022) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-27.3.214 · Cited by 19
de Cacqueray, N., Hirt, D., Zheng, Y., Bille, E., Léger, P. L., Rambaud, J., Toubiana, J., Chosidow, A., Vimont, S., Callot, D., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.05.007 · Cited by 18
Budai, K. A., Tímár, Á. E., Obeidat, M., Máté, V., Nagy, R., Harnos, A., Kiss‐Dala, S., Hegyi, P., Garami, M., Hankó, B., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102293 · Cited by 18
Welsch, C., Augustin, P., Allyn, J., Massias, L., Montravers, P., & Allou, N. (2015) · Transplant Infectious Disease · doi:10.1111/tid.12327 · Cited by 18
“Imipenem is frequently used for empirical treatment of nosocomial pneumonia in the intensive care unit (ICU) (2).”
BackgroundSelf-citationBacterial sepsis: Diagnostics and calculated antibiotic therapy
Richter, D., Heininger, A., Brenner, T., Hochreiter, M., Bernhard, M., Briegel, J., Dubler, S., Grabein, B., Hecker, A., Krüger, W. A., et al. (2018) · Der Anaesthesist · doi:10.1007/s00101-017-0396-z · Cited by 22
“(Defining Antibiotic Levels in Intensive Care Unit Patients, DALI; [202]) using the example of β-lactams.”
BackgroundMethodInfluentialZander, J., Döbbeler, G., Nagel, D., Scharf, C., Huseyn‐Zada, M., Jung, J., Frey, L., Vogeser, M., & Zöller, M. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.06.013 · Cited by 18
Chauzy, A., Grégoire, N., Ferrandière, M., Lasocki, S., Ashenoune, K., Séguin, P., Boisson, M., Couet, W. R., Marchand, S., Mimoz, O., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac299 · Cited by 17
Self-citationBektay, M. Y., Sancar, M., Okyaltırık, F., Durdu, B., & İzzettin, F. V. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1049289 · Cited by 17
“Consistent with other studies in the literature, the active participation of the clinical pharmacist in the healthcare team has ensured the prevention of possible or existing DRPs (Daneman et al., 2013; Roberts et al., 2014; Ngocho et al., 2020; Oliver et al., 2021).”
ResultBarreto, E. F., Chitre, P., Pine, K. H., Shepel, K. K., Rule, A. D., Al‐Shaer, M. H., Abdul-Aziz, M. H., Roberts, J. A., Scheetz, M. H., Ausman, S. E., et al. (2023) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001059 · Cited by 17
“To probe these hypotheses, we performed a mixed-methods study to (1) determine ICU practitioners’ perspectives on implementing beta-lactam TDM and (2) comprehensively characterize barriers and facilitators for beta-lactam TDM implementation in real-world practice.”
MethodSelf-citationBarker, C. I. S., Kipper, K., Lonsdale, D., Wright, K., Thompson, G., Kim, M., Turner, M. A., Johnston, A. E., Sharland, M., & Standing, J. F. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad196 · Cited by 17
Miano, T. A., Barreto, E. F., McNett, M., Martin, N. D., Sakhuja, A., Andrews, A., Basu, R. K., & Ablordeppey, E. (2024) · Critical Care Medicine · doi:10.1097/ccm.0000000000006237 · Cited by 18
O’Donnell, J. N., Rhodes, N. J., Lopez, J., Jett, R., & Scheetz, M. H. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2018.04.011 · Cited by 21
Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplantation: Management Principles
Smibert, O. C., Satlin, M. J., Nellore, A., & Peleg, A. Y. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0679-4 · Cited by 18
Indian consensus on the management of CRE infection in critically ill patients (ICONIC) — India
Soman, R. N., Veeraraghavan, B., Hegde, A. V., Jiandani, P., Mehta, Y. B., Nagavekar, V., Rodrigues, C. S., Singh, R. K., Swaminathan, S., Todi, S. K., et al. (2019) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2019.1647103 · Cited by 18
“Renal replacement therapy (RRT) protocols in ICUs vary across different institutions.”
BackgroundInfluentialNiibe, Y., Suzuki, T., Yamazaki, S., Suzuki, T., Takahashi, N., Hattori, N., Nakada, T., Oda, S., & Ishii, I. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000741 · Cited by 17
Antibiotic treatment in patients with sepsis: a narrative review
Plata-Menchaca, E. P., Ferrer, R., Ruiz‐Rodríguez, J. C., Morais, R., & Póvoa, P. M. S. R. (2020) · Hospital Practice · doi:10.1080/21548331.2020.1791541 · Cited by 17
“Antibiotic Levels in Intensive care unit patients (DALI) study, showed a wide range in beta-lactam blood concentrations (>500x fold variation) with one-fifth of patients being unable to achieve the PK/PD targets [151].”
Backgroundde Vroom, S. L., van Daalen, F. V., Zieck, S. E., Mathôt, R. A. A., van Hest, R. M., & Geerlings, S. E. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.11.032 · Cited by 17
Rakete, S., Schuster, C., Paal, M., & Vogeser, M. (2021) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2021.113944 · Cited by 17
Heffernan, A. J., Sime, F. B., Lim, S. M. S., Adiraju, S. K. S., Wallis, S. C., Lipman, J., Grant, G. D., & Roberts, J. A. (2022) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2022.106537 · Cited by 17
Self-citationDried Plasma Spot Based LC–MS/MS Method for Monitoring of Meropenem in the Blood of Treated Patients
Cao, H., Jiang, Y., Wang, S., Cao, H., Li, Y., & Huang, J. (2022) · Molecules · doi:10.3390/molecules27061991 · Cited by 17
Why We May Need Higher Doses of Beta-Lactam Antibiotics: Introducing the ‘Maximum Tolerable Dose’
Dhaese, S. A. M., Hoste, E. A. J., & Waele, J. J. D. (2022) · Antibiotics · doi:10.3390/antibiotics11070889 · Cited by 17
Barreto, E. F., Chang, J. H. T., Bjergum, M. W., Gajic, O., Jannetto, P. J., Mara, K. C., Meade, L. A., Rule, A. D., Vollmer, K. J., Scheetz, M. H., et al. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2766 · Cited by 17
“48 Finally, although we demonstrated early antimicrobial inadequacy in these critically ill patients, we were unable to probe a link to clinical out - comes in this study; however, this has been previously demonstrated in the critically ill. 12,13,15– 17”
BackgroundInfluentialTreatment option for sepsis in children in the era of antibiotic resistance
Lutsar, I., Telling, K., & Metsvaht, T. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.956093 · Cited by 17
Zelenitsky, S. A., Nash, J., Weber, Z., Iacovides, H., & Ariano, R. E. (2016) · Journal of Chemotherapy · doi:10.1080/1120009x.2016.1140858 · Cited by 17
Pharmacologic Issues in Liver Disease
Gallagher, J., Biesboer, A. N., & Killian, A. J. (2016) · Critical Care Clinics · doi:10.1016/j.ccc.2016.02.003 · Cited by 17
Optimization of anti-infective dosing regimens during online haemodiafiltration
Jager, N. G. L., Zandvliet, A. S., Touw, D. J., & Penne, E. L. (2017) · Clinical Kidney Journal · doi:10.1093/ckj/sfx009 · Cited by 17
Avedissian, S. N., Skochko, S. M., Lê, J., Hingtgen, S., Harvey, H. A., Capparelli, E. V., Richardson, A. C., Momper, J. D., MAK, R. H. K., Neely, M. N., et al. (2020) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-25.5.413 · Cited by 18
Lechtig, S., Liebisch-Rey, H., Díaz-Pinilla, N., Blanco, J., Fuentes, Y. V., & Bustos, R. (2021) · Antibiotics · doi:10.3390/antibiotics10020177 · Cited by 17
“We performed a systematic review as per the guidelines established by the Cochrane Collaboration [49] and the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) statement [41] on EMBASE, PubMed/MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.”
BackgroundMethodPadullés, A., Roig, R. J., Badosa, E. L., Sabater‐Riera, J., Pérez-Fernández, X. L., Cárdenas-Campos, P., Rigo-Bonnin, R. F., Ramos, P. A., Tubau, F., Martinez, E. S., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz299 · Cited by 16
Vasikasin, V., Rawson, T. M., Holmes, A. H., & Otter, J. A. (2023) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlad036 · Cited by 16
State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms
Yassin, A., Huralska, M., Pogue, J. M., Dixit, D., Sawyer, R. G., & Kaye, K. S. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad499 · Cited by 17
Li, X., Long, Y., Wu, G., Li, R., Zhou, M., He, A., & Jiang, Z. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01222-w · Cited by 19
“In critically ill patients, unpredictable pharmacokinetics are often caused by organ perfusion changes and dysfunction, which often results in inadequate antibiotic exposure, potentially reducing efficacy and promoting the emergence of resistance bacteria [7, 37].”
Antimicrobial Pharmacokinetics and Pharmacodynamics
Jarrell, A. S., Kruer, R. M., Johnson, D., & Lipsett, P. A. (2015) · Surgical Infections · doi:10.1089/sur.2014.180 · Cited by 17
Léone, M., Roberts, J. A., Bassetti, M., Bouglé, A., Lavigne, J.-P., Legrand, M. M., Neely, M. N., Paiva, J.-A., Payen, D. M., Rello, J., et al. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.09.009 · Cited by 17
Self-citationDerendorf, H., Heinrichs, T., Reimers, T., Lebert, C., & Brinkmann, A. (2020) · GMS infectious diseases · doi:10.3205/id000061 · Cited by 18
Gijsen, M., Bekkers, B., Maertens, J. A., Lagrou, K., Desmet, S., Dreesen, E., Peetermans, W. E., Debaveye, Y. A., & Spriet, I. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106472 · Cited by 16
Tiede, C., Chiriac, U., Dubinski, D., Raimann, F. J., Frey, O. R., Röhr, A. C., Wieduwilt, A., Eibach, M., Filmann, N., Senft, C., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10111421 · Cited by 16
O’Donnell, J. N., Venkatesan, N., Manek, M., Rhodes, N. J., & Scheetz, M. H. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp150170 · Cited by 16
Ullah, S., Beer, R., Fuhr, U., Taubert, M., Zeitlinger, M. A., Kratzer, A., Dorn, C., Arshad, U., Kofler, M., & Helbok, R. (2020) · Neurocritical Care · doi:10.1007/s12028-020-00947-x · Cited by 16
Tan, W. W., Watt, K., Boakye‐Agyeman, F., Cohen‐Wolkowiez, M., Mok, Y. H., Yung, C. F., & Chan, Y. H. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1798 · Cited by 16
Cies, J. J., Moore, W. S., Parker, J., Stevens, R. M., Al-Qaqaa, Y. M., Enache, A., & Chopra, A. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky574 · Cited by 16
Dräger, S., von Rotz, M., Labhardt, N. D., Siegemund, M., Rentsch, K., Osthoff, M. F., & Franzeck, F. C. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad143 · Cited by 19
“…that the free drug concentration ( f T) of β -lactam antibiotics is maintained above the minimal inhibitory concentration (MIC) of the underlying path-ogen during the entire dosing interval (100% f T > MIC ) to improve clinical outcome [1, 2, 10–14] and to enhance bacterial killing [15–18].”
Novy, E., Abdul-Aziz, M. H., Cheng, V., Burrows, F. S., Buscher, H., Corley, A., Diehl, A., Gilder, E., Levkovich, B., McGuinness, S., et al. (2023) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01201-23 · Cited by 15
Self-citationCeftazidime-avibactam induced renal disorders: past and present
Shi, Y., Wu, J., Mi, W., Zhang, X., Ren, X., Shen, C., & Lu, C. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1329307 · Cited by 15
A systematic review of antimicrobial stewardship interventions implemented in intensive care units
Ntim, O. K., Opoku‐Asare, B., & Donkor, E. S. (2025) · Journal of Hospital Infection · doi:10.1016/j.jhin.2025.04.020 · Cited by 18
Shortening the course of antibiotic treatment in the intensive care unit
Barrett, J., Edgeworth, J., & Wyncoll, D. L. A. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1008451 · Cited by 22
“, above the target MIC) for less than 50% of the interval time between doses [45].”
BackgroundBurnham, J. P., Micek, S. T., & Kollef, M. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180247 · Cited by 15
Hatti, M., Solomonidi, N., Odenholt, I., Tham, J., & Resman, F. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3194-x · Cited by 15
Abdul-Aziz, M. H., Driver, E., Lipman, J., & Roberts, J. A. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1484452 · Cited by 15
Self-citationÖzger, H. S., Fakıoğlu, D. M., Erbay, K., Albayrak, A., & Hızel, K. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05005-7 · Cited by 15
Stitt, G. A., Dubinsky, S., Edginton, A. N., Huang, Y.-S. V., Zuppa, A. F., Watt, K., & Downes, K. J. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.889958 · Cited by 15
“Further, multiple studies in adult and pediatric populations have shown that traditional, weight-based dosing regimens do not reliably achieve antibiotic targets associated with improved clinical outcomes (10, 14, 15).”
BackgroundCheng, Y., Chen, M., Zhang, B., Lin, H., Li, X., Cai, Y., Zhang, H., Que, W., Liu, M., & Qiu, H. (2022) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13693 · Cited by 15
Martín‐Loeches, I., Shorr, A. F., Wunderink, R. G., Kollef, M. H., Timsit, J., Yu, B., Huntington, J. A., Jensen, E. H., & Bruno, C. J. (2023) · Annals of Intensive Care · doi:10.1186/s13613-022-01084-8 · Cited by 15
Bavaro, D. F., Belati, A., Diella, L., Frallonardo, L., Guido, G., Papagni, R., Pellegrino, C., Brindicci, G., Gennaro, N. D., Gennaro, F. D., et al. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad215 · Cited by 15
Fournier, A., Goutelle, S., Que, Y., Eggimann, P., Pantet, O., Sadeghipour, F., Voirol, P., & Csajka, C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00505-18 · Cited by 15
Olbrisch, K., Kisch, T., Thern, J., Kramme, E., Rupp, J., Graf, T., Wicha, S. G., Mailänder, P., & Raasch, W. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1573-6 · Cited by 15
Herregodts, J., Vooren, S. V., Deschuyteneer, E., Dhaese, S. A. M., Stove, V. V., Verstraete, A., & Waele, J. J. D. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.01.025 · Cited by 15
Rimmler, C., Lanckohr, C., Akamp, C., Horn, D., Fobker, M., Wiebe, K., Redwan, B., Ellger, B., Köck, R., & Hempel, G. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14121 · Cited by 17
Aardema, H., Bult, W., van Hateren, K., Dieperink, W., Touw, D. J., Alffenaar, J. C., & Zijlstra, J. G. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz463 · Cited by 15
Oxygenator Impact on Ceftaroline in Extracorporeal Membrane Oxygenation Circuits
Cies, J. J., Moore, W. S., Giliam, N., Low, T., Enache, A., & Chopra, A. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001693 · Cited by 15
Antibiotic dosing in obesity: a BIG challenge
Hanrahan, T. P., Lipman, J., & Roberts, J. A. (2016) · Critical Care · doi:10.1186/s13054-016-1426-y · Cited by 15
“Particularly in critical illness where dramatic changes in antibiotic concentrations can occur with similar doses, accepting guidelines as dosing rules is likely to be flawed [2].”
BackgroundSelf-citationAntibiotic dosing optimization in critically ill patients
Koulenti, D., Roger, C., & Lipman, J. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-07822-3 · Cited by 15
“The great variability in plasma antibiotic concentrations resulting from the distorted pathophysiology-altered PKs in critically ill patients is now well described, and is particularly prominent in specific subgroups (ARC, obese, burns, renal replacement therapy) [3, 5–7].”
Self-citationDebray, A., Callot, D., Hirt, D., Bille, E., Renolleau, S., Chouchana, L., Tréluyer, J., Oualha, M., & Béranger, A. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04716-0 · Cited by 14
“In order to achieve a power of 80% (alpha risk of 5%) under the assumed probabilities that 40% and 75% of the patients would attain the PK target in the II and CI groups, respectively [25], the study should include at least 30 antibiotic courses in each group.”
Schatz, L. M., Greppmair, S., Kunzelmann, A. K., Starp, J., Brinkmann, A., Roehr, A. C., Frey, O. R., Hagel, S., Dorn, C., Zöller, M., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107305 · Cited by 14
Janssen, P. K. C., Foudraine, N. A., Burgers, D. M. T., Neef, K., & le Noble, J. L. M. L. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000330 · Cited by 14
“The results of a landmark study of critically ill patients demonstrated that such patients had a high probability of receiving inadequate antibiotic doses, even for frequently encountered lower MIC values such as 4, 2, or 1 mg/L.(27) Factors that can govern the extent of cefuroxime removal in our study could be classi…”
Antibiotic dosing for multidrug-resistant pathogen pneumonia
Abdul-Aziz, M. H., Lipman, J., & Roberts, J. A. (2016) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000348 · Cited by 17
Self-citationAardema, H., Panday, P. V. N., Wessels, A. M. A., van Hateren, K., Dieperink, W., Kosterink, J. G. W., Alffenaar, J. C., & Zijlstra, J. G. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.02.020 · Cited by 16
“Large recent studies analysing conventional dosing of -lactams showed similar results, where pre-defined targets were not met in a large proportion of patients [13,15].”
ResultEisert, A., Lanckohr, C., Frey, J., Frey, O. R., Wicha, S. G., Horn, D., Ellger, B., Schuerholz, T., Marx, G., & Simon, T.-P. (2021) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2021.106289 · Cited by 15
Buning, A. W., Hodiamont, C. J., Lechner, N. M., Schokkin, M., Elbers, P., Juffermans, N. P., Mathôt, R. A. A., de Jong, M. D., & van Hest, R. M. (2021) · Antibiotics · doi:10.3390/antibiotics10060612 · Cited by 14
Richter, D., Dietrich, M., Lalev, L. D., Schmitt, F. C. F., Fiedler, M. O., Bruckner, T. M., Störzinger, D., Chiriac, U., Klein, S., Hackert, T., et al. (2021) · Antibiotics · doi:10.3390/antibiotics10060687 · Cited by 16
“Abdul-Aziz and co-workers performed a post-hoc analysis [23] of the DALI study [22] to investigate effects of PI on patient mortality and found significantly higher 30-day-survival rates for patients receiving PI for respiratory infections (PI 86.”
BackgroundInfluentialVariability of Beta-Lactam Broth Microdilution for Pseudomonas aeruginosa
Bhalodi, A. A., Oppermann, N., Campeau, S. A., & Humphries, R. M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00640-21 · Cited by 15
Dose optimisation of antibiotics used for meningitis
Heffernan, A. J., & Roberts, J. A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000783 · Cited by 15
Self-citationDreesen, E., Gijsen, M., Elkayal, O., Annaert, P., Debaveye, Y. A., Wauters, J., Karlsson, M. O., & Spriet, I. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac209 · Cited by 14
Self-citationCoyne, A. J. K., Al‐Shaer, M. H., Casapao, A. M., Venugopalan, V., Isache, C. L., Ferreira, J., & Jankowski, C. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00646-22 · Cited by 14
Luxton, T., King, N. V., Wälti, C., Jeuken, L. J. C., & Sandoe, J. A. T. (2022) · Antibiotics · doi:10.3390/antibiotics11101311 · Cited by 14
“Clinical studies have reported associations between PK/PD indices and clinical outcomes in carbapenems [16,17,19,24,25]; however, carbapenem TDM is a complex intervention and there are a number of factors that can impact its effectiveness [26,37].”
BackgroundThe Influence of Extracorporeal Membrane Oxygenation on Antibiotic Pharmacokinetics
Peitz, G. J., & Murry, D. J. (2023) · Antibiotics · doi:10.3390/antibiotics12030500 · Cited by 17
“Of note, the interquartile range of the trough in the ASAP ECMO trial illustrated a much larger range of values than seen by Kuhn et al. Both assessments of Cmin values in the ASAP ECMO study as well as data from Kuhn et al., demonstrate higher trough concentrations than the assessment in the DALI study.”
BackgroundMethodResultInfluentialWeber, N., Jackson, K., McWhinney, B. C., Ungerer, J. P. J., Kennedy, G., Lipman, J., & Roberts, J. A. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.02.014 · Cited by 14
Self-citationMeningitis and encephalitis management in the ICU
Robinson, C. P., & Busl, K. M. (2019) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000640 · Cited by 16
Development of Population and Bayesian Models for Applied Use in Patients Receiving Cefepime
Liu, J., Neely, M. N., Lipman, J., Sime, F. B., Roberts, J. A., Kiel, P. J., Avedissian, S. N., Rhodes, N. J., & Scheetz, M. H. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00873-3 · Cited by 14
Self-citationCeftriaxone dosing in patients admitted from the emergency department with sepsis
Heffernan, A. J., Curran, R. A., Denny, K. J., Sime, F. B., Stanford, C. L., McWhinney, B. C., Ungerer, J. P. J., Roberts, J. A., & Lipman, J. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-03001-z · Cited by 14
Self-citationLiu, J., Zhang, S., Huang, S., Chen, Y., Zhang, L., Du, H., Wang, T., Liu, Y., Xu, Y., & Chen, D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.584813 · Cited by 14
“Depending on illness 333 (9) 325 (11) 8 (1) Infection by nonresistant bacteria 201 (5) 180 (6) 21 (3)”
BackgroundZhou, Q., He, B., Shen, N., Liang, Y., & Sun, L. (2017) · Drugs & Aging · doi:10.1007/s40266-016-0431-9 · Cited by 14
Severe viral pneumonia in adults: what is important for the ICU physician?
Gattarello, S., & Rello, J. (2017) · Hospital Practice · doi:10.1080/21548331.2017.1345280 · Cited by 14
“seems not to be the case when enteral oseltamivir treatment is initiated [20]; in a study performed in ICU patients with pH1N1 infection, enteral absorption and plasmatic levels of Oseltamivir were therapeutic when a dose of 75 mg twice daily was delivered [21].”
BackgroundSelf-citationSartelli, M., Weber, D., Ruppé, É., Bassetti, M., Wright, B. J., Ansaloni, L., Catena, F., Coccolini, F., Abu‐Zidan, F. M., Coimbra, R. S. M., et al. (2017) · World Journal of Emergency Surgery · doi:10.1186/s13017-017-0147-0 · Cited by 14
Self-citationEmerging drugs for nosocomial pneumonia
Liapikou, A., & Torres, A. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1206077 · Cited by 13
Self-citationChai, M. G., Roberts, J. A., Kelly, C. F., Ungerer, J. P. J., McWhinney, B. C., Lipman, J., Farkas, A., & Cotta, M. O. (2023) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2023.101296 · Cited by 13
Self-citationAlnezary, F. S., Almutairi, M. S., Gonzales-Luna, A. J., & Thabit, A. K. (2023) · Antibiotics · doi:10.3390/antibiotics12091441 · Cited by 16
Nesseler, N., Verdier, M., Launey, Y., Malherbe, A., Dermu, M., Piau, C., Flecher, E. M., Tribut, O., Mallédant, Y., & Séguin, P. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02624-14 · Cited by 13
Choosing wisely: what is the actual role of antimicrobial stewardship in Intensive Care Units?
Montrucchio, G. G., Sales, G., Corcione, S., Rosa, F. G. D., & Brazzi, L. (2019) · Minerva Anestesiologica · doi:10.23736/s0375-9393.18.12662-9 · Cited by 15
Petersson, J., Giske, C. G., & Eliasson, E. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02029-20 · Cited by 13
Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels
Hosmann, A., Ritscher, L., Burgmann, H., al Jalali, V., Wulkersdorfer, B., Wölfl‐Duchek, M., Sanz-Codina, M., Jäger, W. R., Poschner, S., Plöchl, W., et al. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab286 · Cited by 13
Schrader, N., Riese, T., Kurlbaum, M., Meybohm, P., Kredel, M., Surat, G., Scherf‐Clavel, O., Strate, A., Andreas, P., & Hoppe, K. (2021) · Antibiotics · doi:10.3390/antibiotics10121452 · Cited by 13
Kumta, N., Heffernan, A. J., Cotta, M. O., Wallis, S. C., Livermore, A., Starr, T., Wong, W. T., Joynt, G. M., Lipman, J., & Roberts, J. A. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00142-22 · Cited by 13
“MIC of 100% has been associated with improved outcomes in other infection syndromes (7, 10, 11).”
BackgroundSelf-citationQuan, T. A., Co, D. X., Vu, D. H., Nguyen, H. A., Gam, T. H., Tran, N. T., Tran, N. M., Vu, N. B., Pham, H. N., Bui, V. C., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00321-22 · Cited by 13
Self-citationChai, M. G., Roberts, J. A., Farkas, A., & Cotta, M. O. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkac392 · Cited by 13
Self-citationDomes, C., Popp, J., Hagel, S., Pletz, M. W., & Frosch, T. (2023) · The Analyst · doi:10.1039/d3an00402c · Cited by 13
Abdul-Aziz, M. H., Rahman, A. N. A., Nor, M. B. M., Sulaiman, H., Wallis, S. C., Lipman, J., Roberts, J. A., & Staatz, C. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01543-15 · Cited by 13
Self-citation
Metadata
- Authors
- Roberts, J. A., Paul, S. K., Akova, M., Bassetti, M., De Waele, J. J., Dimopoulos, G., Kaukonen, K.-M., Koulenti, D., Martin, C., Montravers, P., Rello, J., Rhodes, A., Starr, T., Wallis, S. C., Lipman, J., Study, D., Roberts, J. A., Lipman, J., Starr, T., Wallis, S. C., Paul, S. K., Margarit Ribas, A., De Waele, J. J., De Crop, L., Spapen, H., Wauters, J., Dugernier, T., Jorens, P., Dapper, I., De Backer, D., Taccone, F. S., Rello, J., Ruano, L., Afonso, E., Alvarez-Lerma, F., Gracia-Arnillas, M. P., Fernandez, F., Feijoo, N., Bardolet, N., Rovira, A., Garro, P., Colon, D., Castillo, C., Fernado, J., Lopez, M. J., Fernandez, J. L., Arribas, A. M., Teja, J. L., Ots, E., Carlos Montejo, J., Catalan, M., Prieto, I., Gonzalo, G., Galvan, B., Blasco, M. A., Meyer, E., Del Nogal, F., Vidaur, L., Sebastian, R., Garde, P. M., Martin Velasco, M. D. M., Zaragoza Crespo, R., Esperatti, M., Torres, A., Montravers, P., Baldesi, O., Dupont, H., Mahjoub, Y., Lasocki, S., Constantin, J. M., Payen, J. F., Martin, C., Albanese, J., Malledant, Y., Pottecher, J., Lefrant, J.-Y., Jaber, S., Joannes-Boyau, O., Orban, C., Ostermann, M., McKenzie, C., Berry, W., Smith, J., Lei, K., Rubulotta, F., Gordon, A., Brett, S., Stotz, M., Templeton, M., Rhodes, A., Ebm, C., Moran, C., Kaukonen, K.-M., Pettila, V., Dimopoulos, G., Koulenti, D., Xristodoulou, A., Theodorou, V., Kouliatsis, G., Sertaridou, E., Anthopoulos, G., Choutas, G., Rantis, T., Karatzas, S., Balla, M., Papanikolaou, M., Myrianthefs, P., Gavala, A., Fildisis, G., Koutsoukou, A., Kyriakopoulou, M., Petrochilou, K., Kompoti, M., Michalia, M., Clouva-Molyvdas, F.-M., Gkiokas, G., Nikolakopoulos, F., Psychogiou, V., Malliotakis, P., Akoumianaki, E., Lilitsis, E., Koulouras, V., Nakos, G., Kalogirou, M., Komnos, A., Zafeiridis, T., Chaintoutis, C., Arvaniti, K., Matamis, D., Chaintoutis, C., Kydona, C., Gritsi-Gerogianni, N., Giasnetsova, T., Giannakou, M., Soultati, I., Chytas, I., Antoniadou, E., Antipa, E., Lathyris, D., Koukoubani, T., Paraforou, T., Spiropoulou, K., Bekos, V., Spring, A., Kalatzi, T., Nikolaou, H., Laskou, M., Strouvalis, I., Aloizos, S., Kapogiannis, S., Soldatou, O., Bassetti, M., Adembri, C., Villa, G., Giarratano, A., Maurizio Raineri, S., Cortegiani, A., Montalto, F., Strano, M. T., Ranieri, V. M., Sandroni, C., De Pascale, G., Molin, A., Pelosi, P., Montagnani, L., Urbino, R., Mastromauro, I., De Rosa, F. G., Ranieri, V. M., Cardoso, T., Afonso, S., Goncalves-Pereira, J., Baptista, J. P., Akova, M., & Ozveren, A.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- The University of Queensland (AU)
- Ghent University Hospital (BE)
- Centre Hospitalier Universitaire de Nîmes (FR)
- University General Hospital Attikon (GR)
- Sorbonne Paris Cité (FR)
- St George's, University of London (GB)
- University of Palermo (IT)
- University of Genoa (IT)
- Hacettepe University (TR)
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-14
- Volume
- 58
- Issue
- 8
- Pages
- 1072-1083
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2101416655
- Cited by
- 1,090
- References
- 31
- Citations by year
- 2026: 75 · 2025: 98 · 2024: 83 · 2023: 125 · 2022: 115 · 2021: 125 · 2020: 86 · 2019: 84 · 2018: 69 · 2017: 71 · 2016: 66 · 2015: 57 · 2014: 34
- FWCI
- 55.40
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- HAL (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NIHR/CS/009/007)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- beta-lactam antibiotics, antibiotic dosing, critically ill patients, intensive care unit, pharmacokinetics, pharmacodynamics, free drug concentration, time above MIC, patient outcomes
- MeSH terms
- Aged, Anti-Bacterial Agents, Bacterial Infections, Blood Chemical Analysis, Female, Humans, Intensive Care Units, International Cooperation, Male, Microbial Sensitivity Tests, Middle Aged, Prospective Studies, Models, Statistical, Critical Illness, Treatment Outcome, beta-Lactams
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.